---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-096804"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:22:04.291720+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD narrows Q3 net loss to $567K; license revenue rises to $547K

## Summary
- Net loss from continuing operations of $567K ($0.05 per share) vs. $1.4M loss ($0.13) in Q3 2023.
- License revenue from Mayne agreement totaled $547K, up from negative $53K in Q3 2023.
- Total operating expenses fell 18.3% YoY to $1.4M on cost reductions after royalty transition.
- Cash and equivalents stood at $5.0M as of Sept 30, 2024.
- Company continues to evaluate strategic alternatives including M&A or asset sale; no timeline set.

## SEC filing metadata
- accession: 0001213900-24-096804
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000121390024096804/0001213900-24-096804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000121390024096804/ea0220593-8k_therap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-096804
- JSON: https://secwatch.observer/filing/0001213900-24-096804.json
- Plain text: https://secwatch.observer/filing/0001213900-24-096804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.